Stockscreener 앱 받기
26.54
3.81%
-1.05
전일 마감가:
$27.59
열려 있는:
$27.4923
하루 거래량:
11,806
Relative Volume:
0.49
시가총액:
$104.94M
수익:
$36.84M
순이익/손실:
$-729.00K
주가수익비율:
-28.73
EPS:
-0.9237
순현금흐름:
$-10.02M
1주 성능:
-14.88%
1개월 성능:
-12.87%
6개월 성능:
-27.78%
1년 성능:
+27.66%
1일 변동 폭
$25.95
$27.49
1주일 범위
$25.95
$31.21
52주 변동 폭
$19.50
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
명칭
Vtv Therapeutics Inc
전화
336-841-0300
주소
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
26.54 | 104.94M | 36.84M | -729.00K | -10.02M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2026-03-12 | 개시 | Evercore ISI | Outperform |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2026-01-05 | 개시 | TD Cowen | Buy |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2019-05-30 | 개시 | H.C. Wainwright | Buy |
| 2018-04-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 개시 | Northland Capital | Outperform |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2015-09-04 | 개시 | Canaccord Genuity | Buy |
| 2015-08-24 | 개시 | Piper Jaffray | Overweight |
| 2015-08-24 | 개시 | Stifel | Buy |
모두보기
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
iOnctura appoints Paul Sekhri as Chair of its Board of Directors - GlobeNewswire Inc.
Three parties report shared voting power over vTv Therapeutics (VTVT) shares in a passive stake amendment. - Stock Titan
A new hire gets 2,500 options to buy vTv shares at $31.44 each - Stock Titan
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research - marketbeat.com
Responsive Playbooks and the VTVT Inflection - news.stocktradersdaily.com
Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy - marketbeat.com
vTv Therapeutics (VTVT) Holds Steady at $33.40 as Shares Trade FlatDiamond Pattern - vinanet.vn
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
A type 1 diabetes drug developer plans two investor events in September - Stock Titan
vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving AverageShould You Sell? - marketbeat.com
vTv Therapeutics Q2 2026 Earnings: Net Loss Slightly Wider Than Estimates, Shares Edge HigherPerformance Review - dars.gov.et
vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - kalkine.ca
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High? - qz.com
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
vTv Therapeutics (VTVT) Slips 2.37% to $30.12 as Support Holds in FocusDouble Top - vinanet.vn
vTv Therapeutics (VTVT) Slips 2.37% to $30.12 as Support Holds in FocusActive ETF Flow - dars.gov.et
The Technical Signals Behind (VTVT) That Institutions Follow - Stock Traders Daily
vTv Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Lowers Earnings Estimates for vTv Therapeutics - MarketBeat
vTv Therapeutics Inc (VTVT) Reports Q2 Loss of $1.05 Per Share -- What Does a GF Score of 26/100 Indicate? - GuruFocus
vTv Therapeutics Inc (VTVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
vTv Therapeutics Inc (VTVT) Stock News Today - TradingKey
vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - Kalkine
vTv Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
vTv Therapeutics (VTVT) Advances Diabetes Treatment Amid High Pr - GuruFocus
VTVT Maintains Buy Rating -- Price Target Lowered to $42.00 by H - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright - MarketBeat
VTv Therapeutics: Q2 Earnings Snapshot - marketscreener.com
VTv Therapeutics: Q2 Earnings Snapshot - aol.com
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo! Finance Canada
VTV THERAPEUTICS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $42 FROM $45 - Bitget
vTv Therapeutics (VTVT) Holds Near $34.45 as Traders Eye $36.17 ResistanceVolume Breadth - dars.gov.et
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance Singapore
VTVT Q2'26 Earnings: revenue estimate is 333.33K USD - TradingView
vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Precision Trading with Vtv Therapeutics Inc. (VTVT) Risk Zones - Stock Traders Daily
vTv Therapeutics (VTVT) Edges Down 1% to $32.35, Holding Gains Above Key SupportMotive Wave - dars.gov.et
vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving AverageHere's What Happened - marketbeat.com
vTv Therapeutics (VTVT) Edges Down 1% to $32.35, Holding Gains Above Key SupportQuality ETF - vinanet.vn
vTv Therapeutics Inc. Revenue Breakdown – NASDAQ:VTVT - tradingview.com
vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
vTv Therapeutics (VTVT): Millennium entities disclose 6.9% ownership of Class A shares - Stock Titan
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vtv Therapeutics Inc (VTVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):